A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Helena Cortez‐Pinto et al.|Hepatology|2023Cited by 2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Jeffrey V. Lazarus et al.|Journal of Hepatology|2023Cited by 2.7k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Vlad Ratziu et al.|The Lancet|2019Cited by 1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Velimir A. Luketic, Juan F. Gallegos‐Orozco et al.|Gastroenterology|2016Cited by 1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Jeffrey V. Lazarus et al.|Annals of Hepatology|2023Cited by 789